Oral Isotretinoin — A Complete Patient Guide
Who it's for, how to take it, side effects, relapse — explained

What is oral isotretinoin?

Oral isotretinoin (also marketed as Roaccutane, Acnotin, Sotret) is a vitamin A derivative — specifically, 13-cis-retinoic acid. It's the only acne drug that simultaneously addresses all four root mechanisms of acne:

• Reduces sebum production ~80–90% (sebocyte apoptosis)
• Normalizes follicular keratinization (prevents comedones)
• Suppresses C. acnes indirectly (through reduced sebum substrate)
• Anti-inflammatory (downregulates Toll-like receptor 2)

It's the most effective acne treatment available, with cumulative-dose-based protocols achieving long-term remission in ~67% of patients.

Who is a candidate for oral isotretinoin?

Per the 2024 AAD guideline, indications include:

• Severe nodulocystic acne (deep, painful, scarring lesions)
• Moderate acne unresponsive to ≥ 3 months of combined topical + oral antibiotics
• Acne with significant scarring (any severity)
• Acne with major psychosocial impact (BDD, depression linked to skin)
• Acne fulminans (with corticosteroid pre-treatment)
• Recurrent acne despite multiple courses of conventional therapy

Dosing & cumulative target

The standard protocol is a daily dose of 0.5–1 mg/kg/day (typically starting at 0.5 and titrating up), targeting a cumulative dose of 120–150 mg/kg total.

Example: A 60 kg patient targets 7,200–9,000 mg total → at 40 mg/day, the course runs ~6–8 months. Lower doses (10–20 mg/day, "low-dose isotretinoin") have growing evidence for efficacy with fewer side effects but may have higher relapse rates if cumulative dose is sub-target.

Full side-effect spectrum

Mucocutaneous (universal — > 90%)

• Cheilitis (dry, cracked lips) — manage with petrolatum-based balms multiple times daily
• Dry skin / xerosis — heavy moisturizer + ceramide-based products
• Dry eyes / conjunctivitis — preservative-free artificial tears; avoid contact lenses if symptomatic
• Epistaxis (nosebleeds) — saline nasal sprays + petrolatum to nostrils

Laboratory abnormalities (10–25%)

• Elevated triglycerides (most common metabolic effect; usually mild and reversible)
• Elevated cholesterol
• Mild AST/ALT elevation
• Routine monitoring: baseline + 1 month + every 2-3 months thereafter

Musculoskeletal

• Myalgias / arthralgias — common, usually mild
• Avoid intense weight-training during therapy (rare reports of CK elevation, rhabdomyolysis)

Teratogenicity (absolute contraindication in pregnancy)

• Causes severe birth defects: CNS, cardiac, craniofacial, thymic abnormalities
• Females of reproductive age must use ≥ 1 effective contraception (preferably 2 methods) for 1 month before, throughout, and 1 month after treatment
• Monthly pregnancy tests required

Neuropsychiatric (controversial)

• Older observational studies suggested possible link with depression / suicidal ideation
• 2017 systematic review (Huang & Cheng): no clear causal relationship; severe acne itself confers higher depression risk
• Recommendation: screen for mood symptoms before and during treatment; counsel patients to report changes
• NICE NG198 (2023, reconfirmed April 2026): UK prescribers must screen for depression / anxiety / self-harm / suicidal ideation at baseline AND reassess psychological wellbeing at every follow-up visit (with documentation). Refer to mental-health services before starting if concerns are present

Other rare

• Pseudotumor cerebri (especially with concurrent tetracyclines — avoid combination)
• Inflammatory bowel disease — large 2021 cohort study (Wright et al., JAAD) showed no causal link
• Photosensitivity — strict daily SPF 30+ broad-spectrum required

What to avoid during treatment

• Pregnancy — strict contraception (see above)
• Tetracycline antibiotics (doxycycline, minocycline) — risk of pseudotumor cerebri
• Vitamin A supplements — additive toxicity
• Blood donation — for entire treatment + 1 month after (donor blood could reach a pregnant recipient)
• Aggressive cosmetic procedures — laser resurfacing, deep chemical peels, dermabrasion (delay 6 months after stopping)
• Heavy alcohol — additive hepatic stress

After stopping treatment

Most side effects resolve within 1-2 months of discontinuation. Skin oil production gradually returns but usually remains lower than pre-treatment baseline. Photosensitivity normalizes within weeks.

Procedures timing post-isotretinoin:

• Non-ablative laser, IPL, low-energy picosecond toning: usually safe to resume after 1 month
• Ablative resurfacing, fractional CO2, deep peels: wait ≥ 6 months (per 2017 ASDS consensus, Spring et al.)

Relapse rates

Approximately 1/3 of patients relapse within 1-2 years post-treatment. Risk factors for relapse:

• Cumulative dose < 120 mg/kg
• Younger age at treatment (< 16 years)
• Female with hormonal/PCOS-driven acne
• Severe baseline disease

Relapse can be re-treated with another course of isotretinoin or maintained with topical retinoids + spironolactone (in females).

Taiwan NHI coverage vs out-of-pocket

NHI conditional coverage exists for moderate-to-severe acne meeting specific criteria:

• Diagnosis code 706.1 (acne vulgaris)
• Failure of topical + oral antibiotics ≥ 3 months
• Documented severity (cystic, scarring, multiple body areas)
• Pre-authorization required
• Females of reproductive age: signed contraception consent + monthly pregnancy test

Out-of-pocket cost in Taiwan ranges roughly NT$ 80–200 per 10 mg capsule depending on brand. For a 6-month course at 40 mg/day, total can range NT$ 30,000–60,000.

Common myths

Myth: "It's too dangerous, even just one pill." — Properly monitored, isotretinoin has 70+ years of clinical safety data. Most side effects are mild, reversible, and predictable. The contraindications (pregnancy, severe liver disease) are well-defined.

Myth: "I'll lose all my skin oil forever." — Sebum returns gradually after stopping treatment, though typically to a lower set-point than baseline. This is usually a desired outcome.

Myth: "Drinking alcohol is fine." — Heavy alcohol adds hepatic stress; moderate occasional drinks are usually tolerated, but avoid binging.

Myth: "I should stop if I'm in the early purge phase." — A "purge" in weeks 4-8 is normal for some patients (not most). It usually resolves with continued treatment.

Frequently asked questions

Is it safe? — PTT controversy aside? 70+ years of clinical experience. Common side effects (dry lips, dry skin, lipid/liver elevations) are monitorable and reversible. The absolute contraindication is pregnancy (teratogenic). The "suicide risk" controversy: most studies are observational, and severe acne itself confers depression risk; causation is not established. Regular follow-up + reporting mood changes is recommended.

What is cumulative dose and why does it matter? Cumulative dose = body weight (kg) × 120–150 mg/kg. Example: 60 kg ≈ 7,200–9,000 mg total. Daily dose 0.5–1 mg/kg, course 6–9 months. Reaching the cumulative target reduces relapse risk significantly.

How long must I avoid pregnancy? 1 month before starting + entire treatment + 1 month after. Two contraception methods recommended (e.g., OCP + condom). Monthly clinic visits with pregnancy testing. Accidental pregnancy: stop immediately and consult OB/GYN.

Can I do laser during isotretinoin? Wait 6 months after stopping for invasive lasers (ablative resurfacing, fractional CO2, deep chemical peels) — wound healing is impaired. Non-ablative procedures (low-energy picosecond toning, PDL, IPL) often okay but require individual assessment. Routine skincare, moisturization, sunscreen unaffected.

Will I become depressed? Severe acne itself is a depression risk factor. Studies haven't established a causal link with isotretinoin, but mood changes should be reported. Pre-existing depression is not a strict contraindication but warrants close coordination with psychiatry.

References

1. Reynolds RV, Yeung H, Cheng CE, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1-e30. doi:10.1016/j.jaad.2023.12.017 [Source]
2. National Institute for Health and Care Excellence. Acne vulgaris: management (NG198). London: NICE; 2021 (last updated April 2026). Key points: daily dose 0.5-1 mg/kg; cumulative 120-150 mg/kg; mandatory baseline + every-visit mental-health screening (2023 amendment, MHRA-aligned). [Source]
3. Layton AM. The use of isotretinoin in acne. Dermatoendocrinol. 2009;1(3):162-169. [Source]
4. Wright S, et al. Isotretinoin and inflammatory bowel disease — propensity-matched cohort. J Am Acad Dermatol. 2021;84(4):963-971. [Source]
5. Spring LK, et al. Isotretinoin and timing of procedural interventions: 2017 ASDS consensus. JAMA Dermatol. 2017;153(8):802-809. [Source]